Titel

Merkliste
1 Ergebnisse

Construction and Preclinical Evaluation of a 124/125 I‑Labe..:

Yuan Yao (31223) ; Xingguo Hou (13175122) ; Song Liu (9858)...
https://figshare.com/articles/journal_contribution/Construction_and_Preclinical_Evaluation_of_a_sup_124_125_sup_I_Labeled_Specific_Antibody_Targeting_PD-L2_in_Lung_Cancer/21789524. , 2022

Link: https://doi.org/10.1021/acs.molpharmaceut.2c00958.s001

RT Journal
T1 <Title>Construction and Preclinical Evaluation of a 124/125 I‑Labeled Specific Antibody Targeting PD-L2 in Lung Cancer</Title>

UL https://suche.suub.uni-bremen.de/peid=base-ftunivfreestate:oai:figshare.com:article_21789524&Exemplar=1&LAN=DE
				
A1 Yuan Yao (31223)
A1 Xingguo Hou (13175122)
A1 Song Liu (9858)
A1 Teli Liu (4779657)
A1 Yanan Ren (6594209)
A1 Xiaokun Ma (14308808)
A1 Qian Zhang (49333)
A1 Pei Wang (102036)
A1 Qian Guo (107009)
A1 Xiaopan Ma (9358592)
A1 Zhi Yang (124104)
A1 Hua Zhu (131619)
A1 Nan Li (155066)
YR 2022
K1 Medicine
K1 Cell Biology
K1 Biotechnology
K1 Immunology
K1 Cancer
K1 Chemical Sciences not elsewhere classified
K1 time point (<
K1 important emerging molecule
K1 flow cytometry indicated
K1 62 × 10
K1 89 ± 0
K1 75 ± 0
K1 27 ± 0
K1 19 ± 0
K1 11 ± 0
K1 screening potential beneficiaries
K1 46 ± 2
K1 noninvasively detect pd
K1 )- labeled pd
K1 125 </ sup
K1 immune checkpoint inhibitor
K1 first noninvasive quantification
K1 56 ± 3
K1 max </ sub
K1 72 ± 0
K1 pdl2 cells showed
K1 l2 protein level
K1 05 %
K1 respectively
K1 a549 model mice
K1 124 </ sup
K1 pdl2 mice )
K1 higher tumor uptake
K1 immune checkpoint
K1 respectively )
K1 p </
K1 potential reference
K1 pdl2 cells
K1 ligand 2
K1 l2 protein
K1 pdl2 tumor
K1 pdl2 mice
K1 a549 cells
K1 0001 )
K1 tumor tissues
K1 tumor region
K1 higher pd
K1 bearing mice
K1 western blot
K1 radiochemical yields
JF https://figshare.com/articles/journal_contribution/Construction_and_Preclinical_Evaluation_of_a_sup_124_125_sup_I_Labeled_Specific_Antibody_Targeting_PD-L2_in_Lung_Cancer/21789524
LK http://dx.doi.org/https://doi.org/10.1021/acs.molpharmaceut.2c00958.s001
DO https://doi.org/10.1021/acs.molpharmaceut.2c00958.s001
SF ELIB - SuUB Bremen

Export

RefWorks (nur Desktop-Version!)
Flow (Zuerst in Flow einloggen, dann importieren)